Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California. As of June 20, 2025, Kronos Bio, Inc. operates as a subsidiary of Concentra Biosciences, LLC. Show more

Location: 1300 So. El Camino Real, San Mateo, CA, 94402, United States | Website: https://www.kronosbio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

53.65M

52 Wk Range

$0.65 - $1.60

Previous Close

$0.87

Open

$0.88

Volume

54,089

Day Range

$0.87 - $0.88

Enterprise Value

-21.99M

Cash

99.73M

Avg Qtr Burn

-13.59M

Insider Ownership

24.27%

Institutional Own.

31.44%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
KB-9558 Details Multiple myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Lanraplenib +gilteritinib Details Leukemia, Blood cancer, Acute myeloid leukemia, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Entospletinib Details HOXA9/MEIS1-high AML (Acute myeloid leukemia)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Istisociclib/KB-0742 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.